BACKGROUND: Anemia occurs as a comorbidity in from 80% to 85% of patients with myelodysplastic syndromes (MDS): It causes fatigue, increases transfusion needs, and reduces quality of life. Darbepoetin alpha (DA) is an erythropoiesis-stimulating protein (ESP) that is more highly glycosylated and has a longer half-life relative to recombinant human erythropoietin (rHuEPO), thus, allowing less frequent administration, increased convenience, and better compliance. METHODS: This retrospective analysis included 81 patients with MDS who were enrolled at 9 Spanish centers and who received once-weekly, subcutaneous DA (75-300 microg) for 16 weeks. RESULTS: Fifty-five percent of all patients (38 of 69 evaluable patients) achieved responses; 30.4% of were major responses, and 24.6% were minor responses; 64.7% of rHuEPO-naive patients and 45.7% rHuEPO-treated patients responded; and 43.2% had received previous rHuEPO. Most responses (65.8%) occurred at or before Week 8. The median age at diagnosis was 70 years (range, 38-87 years), the median age at the initiation of DA treatment was 75 years (range, 39-91 years), and 56.8% of patients were women. The median time from last ESP dose to DA initiation was 16.8 weeks (range, 0.0-159.0 weeks; <1 week in 53.1% of patients). According to the French-American-British classification system (n = 81 patients), 39.5% had refractory anemia (RA), 46.9% had RA with ringed sideroblasts, 9.9% had RA with excess blasts (RAEB), 1.2% had RAEB in transformation, and 2.5% had chronic myelomonocytic leukemia. According to the International Prognostic Scoring System (n = 47 patients), 55.3% of patients were in the low-risk group, and 36.2% of patients were in the intermediate-1-risk group. The median baseline hemoglobin level was 8.9 g/dL (range, 8.4-9.1 g/dL). The Starting DA dose was 75 microg per week in 3.7% of patients, 150 microg per week in 65.4% of patients, and 300 microg per week in 29.6% of patients (the dose was increased in 18.5% of patients and reduced in 9.9% of patients; median time to dose adjustment, 8 weeks). Five patients received granulocyte colony-stimulating factors. No DA-related adverse reactions occurred. CONCLUSIONS: In the current study, 55% of evaluable patients with MDS safely achieved an erythroid response. Copyright 2006 American Cancer Society.
BACKGROUND:Anemia occurs as a comorbidity in from 80% to 85% of patients with myelodysplastic syndromes (MDS): It causes fatigue, increases transfusion needs, and reduces quality of life. Darbepoetin alpha (DA) is an erythropoiesis-stimulating protein (ESP) that is more highly glycosylated and has a longer half-life relative to recombinant humanerythropoietin (rHuEPO), thus, allowing less frequent administration, increased convenience, and better compliance. METHODS: This retrospective analysis included 81 patients with MDS who were enrolled at 9 Spanish centers and who received once-weekly, subcutaneous DA (75-300 microg) for 16 weeks. RESULTS: Fifty-five percent of all patients (38 of 69 evaluable patients) achieved responses; 30.4% of were major responses, and 24.6% were minor responses; 64.7% of rHuEPO-naive patients and 45.7% rHuEPO-treated patients responded; and 43.2% had received previous rHuEPO. Most responses (65.8%) occurred at or before Week 8. The median age at diagnosis was 70 years (range, 38-87 years), the median age at the initiation of DA treatment was 75 years (range, 39-91 years), and 56.8% of patients were women. The median time from last ESP dose to DA initiation was 16.8 weeks (range, 0.0-159.0 weeks; <1 week in 53.1% of patients). According to the French-American-British classification system (n = 81 patients), 39.5% had refractory anemia (RA), 46.9% had RA with ringed sideroblasts, 9.9% had RA with excess blasts (RAEB), 1.2% had RAEB in transformation, and 2.5% had chronic myelomonocytic leukemia. According to the International Prognostic Scoring System (n = 47 patients), 55.3% of patients were in the low-risk group, and 36.2% of patients were in the intermediate-1-risk group. The median baseline hemoglobin level was 8.9 g/dL (range, 8.4-9.1 g/dL). The Starting DA dose was 75 microg per week in 3.7% of patients, 150 microg per week in 65.4% of patients, and 300 microg per week in 29.6% of patients (the dose was increased in 18.5% of patients and reduced in 9.9% of patients; median time to dose adjustment, 8 weeks). Five patients received granulocyte colony-stimulating factors. No DA-related adverse reactions occurred. CONCLUSIONS: In the current study, 55% of evaluable patients with MDS safely achieved an erythroid response. Copyright 2006 American Cancer Society.
Authors: Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Carlos M De Castro; H Joachim Deeg; James M Foran; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Stephen D Nimer; Margaret R O'Donnell; Mark A Schroeder; Paul J Shami; Richard M Stone; James E Thompson; Peter Westervelt Journal: J Natl Compr Canc Netw Date: 2011-01 Impact factor: 11.908
Authors: Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704
Authors: Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Margaret R O'Donnell; Paul J Shami; Brady L Stein; Richard M Stone; James E Thompson; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Maoko Naganuma Journal: J Natl Compr Canc Netw Date: 2013-07 Impact factor: 11.908
Authors: R Ria; M Moschetta; A Reale; G Mangialardi; A Castrovilli; A Vacca; F Dammacco Journal: Clin Interv Aging Date: 2009-11-18 Impact factor: 4.458
Authors: Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola Journal: Blood Date: 2013-08-26 Impact factor: 22.113